| EAA181 |
The purpose of this study is to determine what consolidation regimen is most effective. Patients cannot get stem cell transplant until first relapse or later. You must have newly diagnosed multiple myeloma (MM). |
Cancer |
Multiple Myeloma |
| EAY191 ComboMATCH |
The purpose of this study is to find targeted therapy for specific gene mutations in metastatic or advanced cancer. You must have progressed on standard of care treatment or have a cancer which has no standard of care treatment. If select mutations are found you may be eligible for a sub-study. |
Cancer |
Genomics |
| EAY191-E4 ComboMATCH |
The purpose of this study is to determine the effectiveness of nilotinib and paclitaxel in patients with prior taxane treated solid tumors. You must have had at least one prior line of therapy in the metastatic setting. |
Cancer |
Solid Tumors |
| ISPY 2 |
This study uses the type of breast cancer you are diagnosed with to determine what treatment you are given. You must be diagnosed with stage 2 or stage 3 breast cancer. This study requires regular MRI's. |
Cancer |
Breast |
| NRG-GI008 |
The purpose of this study to use blood draws looking at the tumor DNA in the blood to determine need for chemotherapy. You must be diagnosed with stage 3 colon cancer. |
Cancer |
Colon |
| NRG-LU008 |
The purpose of this study is to compare chemo and radiation followed by immunotherapy vs SBRT (stereotactic body radiation therapy) to primary tumor follwed by chemo and radiation then immunotherapy. You must be diagnosed with Stage 2 or 3 non-small cell lung cancer (NSCLC). |
Cancer |
Non-Small Cell Lung |
| S1922 |
The purpose of this study is to determine the effectiveness of Ramucirumab and Paclitaxel vs Folfiri chemo. You must be diagnosed with metastatic or unresectable small bowel cancer. |
Cancer |
Small Bowel |
| S2212 |
The purpose of this study is to compare anthracycline-free, taxane-platinum chemo with pembrolizumab to taxane-platinum-anthracycline chemo with pembrolizumab. This study is for people diagnosed with triple negative breast cancer. |
Cancer |
Breast |
| A022101 |
The purpose of this study is to evaluate radiation, ablation and surgery. You must be diagnosed with metastatic colorectal cancer. The primary tumor must be able to surgically resected. |
Cancer |
Colorectal |
| A022102 |
The purpose of this study is to compare effectiveness of mFOLFIRINOX with or without nivolumab and mFOLFOX6 with or without nivolumab . You must have newly diagnosed metastatic HER2 negative gastroesophageal cancer. |
Cancer |
Esophageal |
| Librexia AF |
The purpose of this research study is to compare the effects of an experimental drug, milvexian, to the comparator drug, apixaban, to determine if it is safe and useful in reducing the risk of stroke and blood clots outside the brain (non-central nervous system (CNS) systemic embolism) in participants with atrial fibrillation. |
Heart & Vascular |
Atrial Fibrillation |
| ANT-010/Lilac |
A study to evaluate the effect of the experimental drug abelacimab relative to placebo in subjects with atrial fibrillation/flutter (AF) who are not treated with oral anticoagulants because they have been deemed by their responsible physicians or by their own decision to be unsuitable for currently available oral blood thinners. |
Heart & Vascular |
Atrial Fibrillation |
| Amgen Ocean(a) |
The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a). Patients must have a Lp(a) value of ≥ 200 nmol/L during screening. |
Heart & Vascular |
Cardiovascular Disease |
| Amplitude |
This research study is a way to find out if the Study Drug is safe and if it works to help people with APOL-1 mediated Chronic Kidney Disease. |
Nephrology |
Proteinuric Kidney Disease |
| Complete TAVR |
The purpose of this study is to determine whether restoring blood flow to all blocked or narrowed arteries via percutaneous coronary intervention (PCI) using coronary stents is better than treating the coronary artery disease (CAD) with medications in patients with CAD who had successful transcatheter aortic value replacement (TAVR) with a balloon expandable heart valve. The study will also compare measurements of hemodynamics (blood flow and blood pressure) that are taken during on-table procedures (TAVR and PCI) with those taken by echocardiography (heart ultrasound). |
Heart & Vascular |
Cardiovascular Disease |
| PPP/PAN/PSR |
This study is a registry study. The purpose is to collect information over time about how Medtronic products are working and/or the outcome of the treatment. The registry will be used to support post-market surveillance activities and post-approval studies (e.g., to collect safety and performance information). In addition, it will be used to obtain clinical evidence for the development and improvement of medical devices, therapies, device guidelines, patient services/solutions and provide clinical data to support health economics and clinical outcomes research. The registry is not an experimental clinical study. |
Heart & Vascular |
Cardiac Arrhythmia |
| Arrhythmia Detection After Myocardial Infarction (AID-MI) |
This study will evaluate the use of an insertable cardiac monitor in patients following an acute myocardial infarction (heart attack) to determine if cardiac monitoring results in more rhythm-related findings that change management compared to standard of care post heart attack management in patients who do not receive the insertable cardiac monitor. |
Heart & Vascular |
Cardiac Arrhythmia |
| CREST 2 LOE |
Long-Term Observational Extension of Participants in the CREST-2 Randomized Clinical Trial (C2LOE) |
Heart & Vascular |
Carotid Stenosis |
| Real AF |
Real-world Experience of Catheter Ablation for the Treatment of Symptomatic Paroxysmal and Persistent Atrial Fibrillation Using Novel Contact Force Technologies: REAL AF Registry |
Heart & Vascular |
Atrial Fibrillation |
| S1925 |
The purpose of this study is to compare early intervention with Venetoclax and Obinutuzumab vs delayed therapy in newly diagnosed asymptomatic high0risk patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). You must have been diagnosed with CLL or SLL within the last 12 months. |
Cancer |
Hematology |
| AALL08B1 |
Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) |
Childhood Cancers |
Leukemia |
| AALL0932 |
Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) |
Childhood Cancers |
Leukemia |
| AALL1231 |
A Phase lll Randomized Trial Investigating Bortezomib (NSC#681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) |
Childhood Cancers |
Leukemia |
| AALL1521 |
A Phase 2 study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2 Rearranged and/ or JAK Pathway-Mutant Acute Lymphoblastic Leukemia |
Childhood Cancers |
Leukemia |
| Acoustic Diagnosis of Gastroesophageal Reflux Disease |
Explore a pediatric clinical trial on acoustic diagnosis of gastroesophageal reflux disease, led by Dr. Ira Gewolb, MD. |
Baby/Child |
Reflux Disease |
| ANBL1232 |
Utilizing Response-and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma |
Childhood Cancers |
Blastoma |
| APEC14B1 EveryChild |
A Registry, Eligibility Screening, Biology and Outcome Study |
Childhood Cancers |
Registry |
| Champion AF |
The primary objective of this study is to determine if left atrial appendage closure with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation. |
Heart & Vascular |
Atrial Fibrillation |
| COG-AALL05B1 |
Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens |
Childhood Cancers |
Leukemia |
| COG-AALL1331 |
Risk Stratified Randomized Phase lll Testing of blinatumomab (IND#117467, NCS#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) |
Childhood Cancers |
Leukemia |